Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06568172
Title Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.